Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
SL-28 in Pancreatic adenocarcinoma: NCT07341737 Clinical Landscape Report 2026
18 September 2026
NCT07341737 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fulvestrant in Melanoma: NCT07340619 Clinical Landscape Report 2026
18 September 2026
NCT07340619 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
225Ac-TR2205 in Triple Negative Breast Cancer: NCT07340424 Clinical Landscape Report 2026
18 September 2026
NCT07340424 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belimumab in Lupus Nephritis: NCT07340463 Clinical Landscape Report 2026
18 September 2026
NCT07340463 clinical landscape for Lupus Nephritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
V001-BCMA in Idiopathic Inflammatory Myopathies: NCT07339540 Clinical Landscape Report 2026
18 September 2026
NCT07339540 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Pembrolizumab in Melanoma, Cutaneous Malignant: NCT07349303 Clinical Landscape Report 2026
18 September 2026
NCT07349303 clinical landscape for Melanoma, Cutaneous Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
N17350 in Advanced Malignant Solid Neoplasm: NCT07339176 Clinical Landscape Report 2026
18 September 2026
NCT07339176 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Velinotamig in Systemic Lupus Erythematosus: NCT07348055 Clinical Landscape Report 2026
18 September 2026
NCT07348055 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Mucosal Melanoma: NCT07347444 Clinical Landscape Report 2026
18 September 2026
NCT07347444 clinical landscape for Mucosal Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fluzoparib in Breast Cancer: NCT07353437 Clinical Landscape Report 2026
18 September 2026
NCT07353437 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Triple Negative Breast Cancer: NCT07351487 Clinical Landscape Report 2026
18 September 2026
NCT07351487 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pucotenlimab in Mucosal Melanoma of the Head and Neck: NCT07353073 Clinical Landscape Report 2026
18 September 2026
NCT07353073 clinical landscape for Mucosal Melanoma of the Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development white…